7.2.5. neoadjuvant adjuvant therapy. neoadjuvant therapy currently investigation available clinical trials. pre-surgical setting neoadjuvant tki immune checkpoint therapy demonstrated varying response rates 7-59% retrospective series phase ii trials . presurgical phase ii trial patients vascular thrombus treatment axitinib demonstrated reduction level tumour thrombus 35% patients (7/20) . currently evidence prolonged os neoadjuvant treatment present, data support use outside clinical trials. currently evidence sr (including ten retrospective studies two rcts) adjuvant radiation therapy increases survival . impact os adjuvant tumour vaccination selected patients undergoing nephrectomy t3 renal carcinomas remains unconfirmed [467-471] (le: 1b). similar observation made adjuvant trial girentuximab, monoclonal antibody carbonic anhydrase ix (caix) (ariser study) . present, os data supporting use adjuvant vegfr mtor inhibitors. thus far, several rcts comparing vegfr-tki mtor vs. placebo published [473-481]. s-trac, trial adjuvant sunitinib vs. placebo demonstrated dfs benefit reproduced assure, trial sunitinib sorafenib vs. placebo. due unfavourable ae profile survival advantage, none drugs recommended . 7.2.5.1. pd-1 inhibition: keynote-564 keynote-564 trial first trial report positive primary endpoint data dfs . keynote-564 evaluated pembrolizumab (17 cycles 3-weekly therapy) vs. placebo adjuvant therapy 994 patients intermediate (pt2, grade 4 sarcomatoid, n0, m0; pt3, grade, n0, m0) high risk (pt4, grade, n0, m0; pt stage, grade, n+, m0), m1 (no evidence disease [ned] primary tumour plus soft tissue metastases completely resected < one year nephrectomy) disease. median follow-up, defined time randomisation data cut-off, 24.1 months. primary endpoint dfs per investigator assessment significantly improved pembrolizumab group vs. placebo (hr: 0.68, 95% ci: 0.53–0.87, p = 0.001). estimated 24-month dfs rate 77% vs. 68% pembrolizumab placebo, respectively. benefit occurred across broad subgroups patients including m1/ned disease post-surgery (n = 58 [6%]). investigator assessed dfs considered preferable dfs central review due clinical applicability. overall survival showed non-statistically significant trend towards benefit pembrolizumab arm (hr: 0.54, 95% ci: 0.30-0.96, p = 0.0164). follow-up short os events occurred (2-year os rate 97% [pembrolizumab] vs. 94% [placebo]). grade iii-v all-cause aes occurred 32% vs. 18% patients pembrolizumab placebo, respectively. quality life assessment fksi-drs qlq30 show statistically significant clinically meaningful deterioration health-related qol symptom scores either adjuvant pembrolizumab placebo. 7.2.5.2. pd-l1 inhibition: immotion010 immotion010 phase iii trial first adjuvant ici trial developed rcc investigate effect pd-l1 inhibitor dfs . immotion010 evaluated atezolizumab 1200 mg (once every 3 weeks 16 cycles one year) vs. placebo adjuvant therapy 778 patients increased risk recurrence defined as: pt2, grade 4 sarcomatoid, n0, m0; pt3, grade 3–4, n0, m0; pt3b/c/t4, grade, n0, m0; pt stage grade, pn1, m0, m1 ned primary tumour plus soft tissue metastases completely resected either synchronous metachronous, > 12 months nephrectomy. minimum follow-up, defined time randomisation data cut-off, 38.6 months. primary endpoint dfs per investigator assessment met atezolizumab group vs. placebo (hr: 0.93, 95% ci: 0.75-1.15, p = 0.4950) median dfs 57.2 months (95% ci: 44.6, ne) atezolizumab vs. 49.5 months placebo (47.4, ne). none exploratory subgroups suggested dfs benefit atezolizumab, notably m1 ned subgroup (n = 108/13.9%) larger keynote-564 (5.8%), sarcomatoid subgroup subgroup expressing > 1% pd-l1 hr 0.93 (0.58–1.49), 0.77 (0.44–1.36) 0.83 (0.63-1.10), respectively. os differences. grade 3-4 all-cause treatment-related aes occurred 27.2% 14.1% vs. 21.1% 4.7% patients atezolizumab placebo, respectively. treatment-related grade 5 aes. 7.2.5.3. pd-1 ctla-4 inhibition: checkmate 914 checkmate 914 first phase iii trial investigate combination nivolumab plus ipilimumab vs. placebo adjuvant treatment rcc (part a) . subsequently, nivolumab monotherapy arm also added trial (part b). following results relate part evaluated nivolumab 240 mg every two weeks (q2w) 12 cycles 6 months plus ipilimumab 1 mg/kg q6w 4 cycles vs. placebo 816 patients recurrence risk defined pt2a, grade 3 4, n0, m0; pt2b/t3/t4, grade, n0, m0, pt stage, grade, pn1, m0. median time follow-up, defined time randomisation data cut-off, 37 months. primary endpoint dfs per investigator assessment met nivolumab plus ipilimumab group vs. placebo (hr 0.92 [0.71-1.19], p = 0.5347). exploratory subgroups, patients sarcomatoid tumours (n = 40) > 1% pd-l1 expression (n = 107) hr 0.29 (0.09-0.91) 0.46 (0.23-0.94) favour ici combination, respectively. all-cause treatment discontinuation due study drug occurred 43% 33% nivolumab plus ipilimumab group vs. 11% 1% placebo group. treatment-related ae grade > iii 29% nivolumab plus ipilimumab group 2% placebo group four deaths (1%) considered related combination therapy. high ae profile may contributed lack efficacy patient retention. results nivolumab arm awaited. 7.2.5.4. perioperative pd-1 inhibition: prosper prosper peri-operative trial neoadjuvant nivolumab (one cycle) followed radical partial nephrectomy adjuvant nivolumab (480 mg iv q4 weeks) nine doses compared surgery followed surveillance without placebo . patients clinical stage > t2 n+ rcc patients selected oligometastatic disease included evidence disease within 12-weeks post- surgery. total 819 patients clear cell (87%) non-ccrcc included, biopsy nivolumab arm mandatory. primary endpoint rfs similar arms (hr: 0.97; 95% ci: 0.74-1.28; p = 0.43) trial stopped dsmc. os statistically different (hr: 1.48; 95% ci: 0.89-2.48; p = 0.93), although mature. grade iii-iv aes occurred 20% (nivolumab arm) 6% (control arm) patients, respectively. fifteen (4%) patients died nivolumab arm eighteen (4%) surgery alone arm. following application eau guidelines methodology, panel reached consensus issued weak recommendation adjuvant pembrolizumab patients high-risk (defined per study) operable ccrcc final os data available . decision taken immune checkpoint inhibitor therapy different mode action vegfr-tki resulting complete responses 16% patients pd-1 unselected populations metastatic disease . despite immature os data early os signal potentially driven m1 population panel cannot exclude survival benefit emerge. case adjuvant sunitinib trial (strac) . panel took following evidence limitations account deciding make weak recommendation adjuvant pembrolizumab: high proportion patients, cured surgery, receiving unnecessary, potentially harmful treatment.the tolerability profile acceptable grade iii-v aes higher 14.7% pembrolizumab arm vs. placebo arm (occurring approximately one-third patients, cause). approximately 18% patients required treatment discontinuation early aes gives broad indicator tolerability. significant risk life-changing toxicity.other ici trials shown consistent results.biomarker analysis predict outcome aes available.final os data yet available. results immotion010, checkmate 914 prosper need discussed patients [485-487]. meta-analysis data sets recommended due heterogeneity across ici studies. likely several reasons behind inconsistent results, including study population potential heterogeneity independent tnm risk groups, selection criteria trial design. date pembrolizumab positive trial . results immotion010 may reflect non-significant os results seen metastatic setting pd-l1 inhibitors (immotion151, javelin 101), results checkmate 914 prosper difficult interpret. nivolumab ipilimumab leads durable remission long-term os metastatic disease nivolumab similar mode action pembrolizumab (anti pd-1). high treatment discontinuation rate 33% checkmate 914 concern may impact trial effectivity (20% keynote-564). panel strongly feels biomarker work trials occur identify patients respond therapy give better explanation inconsistent results. treatment unselected patients adjuvant setting based keynote-564 criteria result large proportion patients receiving unnecessary therapy. absence os data appropriate biomarkers, patient preference leading shared decision-making process. patients considering adjuvant therapy aware trials presented one data set. table 7.1: overview phase iii trials pd-1 immune checkpoint inhibitors adjuvant rcc phase iii trial pd-1 immune checkpoint inhibitors adjuvant rccstudynexperimental armprimary endpointrisk groupsdfs (mo)median (95% ci) hros (mo.)median (95% ci) hrkeynote-564nct03142334median follow-up 30.1 mo. 994pembro 200 mg iv q3w (17 cycles) vs.placebodfs itt irintermediate-high: pt2 grade 4 sarcomatoid; pt3 gradehigh: pt4 grade, pn1m1 ned: cm0 resection oligometastatic disease < 12 mo.(itt)pembro: nr (ne)placebo: nr (ne)hr: 0.63 (95% ci: 0.50-0.80))p < 0.002dfs 24 mo.:pembro: 78.3%placebo: 67.3%(itt)pembro: nr (ne)placebo: nr (ne)hr: 0.52 (95% ci: 0.31-0.86)not significantalive 30 mo.:pembro: 95.7%placebo: 91.4%immotion010nct03024996median follow-up 44.7 mo. 778atezo 1200 mg iv q3w (16 cycles 1 yr.) vs. placebodfs itt irby tnm:pt2 grade 4 sarcomatoid; pt3 grade 3-4; pt3b/c/t4 grade, pn1m1 ned: cm0 resection oligometastatic disease (synchronous >/=12 mo.)(itt)atezo: 57.2(44.6-ne)placebo: 49.5 (47.4-ne)hr: 0.93 (95% ci: 0.75-1.15)p = 0.4950dfs 24 mo.: nr(itt)atezo : ne(59.8-ne)placebo : ne(ne-ne)hr : 0.97 (95% ci: 0.67-1.42)alive 24 mo.: nrcheckmate 914nct03138512median follow-up 37.0 mo.816nivo 240 mg iv q2w(× 12 cycles) + ipilimumab 1 mg/kg iv q6w (× 4 cycles vs. placebo)dfs itt bicrby tnm:pt2a grade 3-4;pt2b/t3/t4 grade, pn1(itt)nivo + ipi: nr (ne)placebo: 50.7 (48.1-ne)hr: 0.92 (95% ci: 0.71-1.19)p = 0.5347dfs 24 mo.:nivo + ipi: 76.4%placebo: 74.0%nrprospernct03055013median follow-up: nr 779neoadjuvant nivo 240 mg iv q2w (x 2 cycles) followed adjuvant nivolumab 240 mg q2w 3 mo. q4w 6 mo. vs. observationrfs itt irby tnm:>/= ct2 (7 cm) ct cn1(itt), rfs:nivo: nr (ne)observation: nr (ne)hr: 0.97 (95% ci: 0.74-1.28)p = 0.43(itt)nivo : nr (ne)observation : nr (ne)hr: 1.48 (95% ci: 0.89-2.48)p = 0.93 atezo = atezolizumab; bicr = blinded independent central review; ci = confidence interval; dfs = disease-free survival; hr = hazard ratio; ipi = ipilimumab; ir = investigator review; itt = intention-to-treat; iv = intravenous; mo = months; ne = non-estimable; ned = evidence disease; nivo = nivolumab; nr = reached; os = overall survival; pd-1 = programmed death-receptor 1; pembro = pembrolizumab; pfs = progressionfree survival; q2w = every 2 weeks; q3w = every 3 weeks. 7.2.5.5. summary evidence recommendations neoadjuvant adjuvant therapy summary evidenceleneoadjuvant systemic therapy reduce vascular thrombus tumour size presurgical setting.2aadjuvant sorafenib, pazopanib, everolimus, girentuximab, axitinib improve dfs os nephrectomy.1bin one single rct, selected high-risk patients, adjuvant sunitinib improved dfs os.1badjuvant pembrolizumab defined inclusion criteria trial* nephrectomy improves dfs.1badjuvant pd-l1 inhibition atezolizumab improve dfs os.1badjuvant dual pd-1 ctla-4 inhibition nivolumab ipilimumab improve dfs.1bperi-operative treatment nivolumab improve rfs.1bthe lack biomarker data hindering progress field. adjuvant rcts ongoing evaluate benefit adjuvant immunotherapy nephrectomy high-risk patients.4 * pt2 g4 pt3 g; pt4 g; pn+ g; m1, ned resection metastases. recommendationsstrength ratingdo use neoadjuvant therapy outside clinical trial setting.weakdiscuss contradictory results available adjuvant ici trials patients facilitate shared decision making.stronginform patients potential risk overtreatment immune related side effects adjuvant therapy considered.strongdo offer adjuvant therapy sorafenib, pazopanib, everolimus, girentuximab, axitinib.strongdo offer adjuvant sunitinib following surgically resected high-risk clear-cell renal cell carcinoma (ccrcc).weakoffer adjuvant pembrolizumab ccrcc patients, preferably within 12-16 weeks post-nephrectomy, recurrence risk defined keynote-564 trial:intermediate-high risk:- pt2, grade 4 sarcomatoid, n0 m0- pt3, grade, n0, m0high risk:- pt4, grade, n0, m0- pt, grade, n+, m0m1 evidence disease (ned):- ned resection oligometastatic sites ≤ 1 year nephrectomyweak